Sputnik V | Page 3 | The Business Standard
Skip to main content
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Get the Paper
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Sunday
August 17, 2025

Sign In
Subscribe
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Get the Paper
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
SUNDAY, AUGUST 17, 2025

Sputnik V

The calculations were based on preliminary data obtained 42 days after the first dose, Russia's health ministry, the state-run Gamaleya research centre and the Russian Direct Investment Fund (RDIF) said in a statement.  Photo: Reuters
Coronavirus chronicle

Sputnik V can offer two-year protection against Covid-19: Developers

According to the Russian scientist, Sputnik V is effective in 96 percent of cases

Russian President Vladimir Putin attends a meeting of the Collective Security Treaty Organization (CSTO), via a video link at the Novo-Ogaryovo state residence outside Moscow, Russia December 2, 2020. Sputnik/Aleksey Nikolskyi/Kremlin via REUTERS
Coronavirus chronicle

Putin orders Russia to begin large-scale Covid-19 vaccinations next week

Representational image: Reuters
Coronavirus chronicle

Two-shot of Russia's Sputnik V vaccine to cost less than $20 per person - statement

The calculations were based on preliminary data obtained 42 days after the first dose, Russia's health ministry, the state-run Gamaleya research centre and the Russian Direct Investment Fund (RDIF) said in a statement.  Photo: Reuters
World+Biz

Putin says India, China may start producing Russia's Sputnik V Covid-19 vaccine -RIA

South Korean firm to produce 150 million doses of Russian Covid-19 vaccine - RIDF
Coronavirus chronicle

South Korean firm to produce 150 million doses of Russian Covid-19 vaccine - RIDF

Representational image: Reuters
Coronavirus chronicle

Russia says its Sputnik V Covid-19 vaccine is 92% effective

Post-registration trials of Russia's second Covid-19 vaccine expected to start on Nov. 15 -deputy PM
Coronavirus chronicle

Post-registration trials of Russia's second Covid-19 vaccine expected to start on Nov. 15 -deputy PM

Russia's Sputnik V vaccine over 90% effective: health ministry
Coronavirus chronicle

Russia's Sputnik V vaccine over 90% effective: health ministry

However, the US Food and Drug Administration has said vaccines must demonstrate at least 50% efficacy Representational Photo: BSS/AFP
Coronavirus chronicle

Russia seeks accelerated WHO registration for virus vaccine

A nurse prepares Russia's "Sputnik-V" vaccine for inoculation in a post-registration trials stage at a clinic in Moscow. Photo: Reuters
Coronavirus chronicle

Covid-19: India won’t allow trial of Russia’s Sputnik V in large study

A handout photo provided by the Russian Direct Investment Fund (RDIF) shows samples of a vaccine against the coronavirus disease (Covid-19) developed by the Gamaleya Research Institute of Epidemiology and Microbiology, in Moscow, Russia August 6, 2020. Picture taken August 6, 2020. The Russian Direct Investment Fund (RDIF)/Handout via REUTERS
Coronavirus chronicle

First batch of Sputnik V vaccine has been shipped to Russian regions: Health Ministry

A handout photo provided by the Russian Direct Investment Fund (RDIF) shows samples of a vaccine against the coronavirus disease (Covid-19) developed by the Gamaleya Research Institute of Epidemiology and Microbiology, in Moscow, Russia August 6, 2020. Picture taken August 6, 2020. The Russian Direct Investment Fund (RDIF)/Handout via REUTERS
Coronavirus chronicle

Russia releases first batch of Covid-19 vaccine Sputnik V into public

EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net